Please assess the completion status of the following clinical trial:

Trial Title: Zinc Supplement in Regorafenib Treated mCRC Patient

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with mCRC who have been previously treated with, or are not considered candidates for, other locally approved standard treatment(s) and for whom the decision has been made per investigator's routine treatment practice to prescribe regorafenib~* Ability to understand and willingness to sign written Informed Consent Form (ICF)~Exclusion Criteria:~* Patients participating in an investigational program with interventions outside of routine clinical practice~* Patients with baseline Zinc level above 120 ug/dL~* Patients with known allergy to Zinc supplementation~* Pregnancy~* Patients who are unsuitable for study participation, based on investigator's discretion

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Regorafenib treatment with Zn supplement (Type: EXPERIMENTAL): Patients enrolled in this arm received regorafenib with zinc supplementation to examine if zinc supplementation can decrease the incidence of grade 2 or higher HFSR.
- Regorafenib treatment only (Type: ACTIVE_COMPARATOR): Patients enrolled in this arm received regorafenib without zinc supplementation, which is the standard treatment of patients of metastatic colorectal cancer who failed previous standard therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).